Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
About 50% of patients with breast cancer have no involvement of axillary lymph nodes at diagnosis and can be considered cured after primary locoregional treatment. However, about 20-30% will experience distant relapse. The group of patients at risk is not well characterised: recurrence is probably due to the establishment of micrometastases before treatment. Given the early steps of metastasis in which tumour cells interact with endothelial cells of blood vessels, and, given the independent prognostic value in breast cancer of both the quantification of tumour vascularisation and the detection of micrometastases in the bone marrow, the aim of this study was to determine the relationship between vascularisation, measured by Chalkley morphometry, and the bone marrow content of cytokeratin-19 (CK-19) mRNA, quantified by real-time reverse transcriptase polymerase chain reaction, in a series of 68 patients with localised untreated breast cancer. The blood concentration of factors involved in angiogenesis (interleukin-6 and vascular endothelial growth factor) and of factors involved in coagulation (D-dimer, fibrinogen, platelets) was also measured. When bone marrow CK-19 relative gene expression (RGE) was categorised according to the cut-off value of 0.77 (95th centile of control patients), 53% of the patients had an elevated CK-19 RGE. Patients with bone marrow micrometastases, on the basis of an elevated CK-19 RGE, had a mean Chalkley count of 7.5 +/- 1.7 (median 7, standard error [SE] 0.30) compared with a mean Chalkley count of 6.5 +/- 1.7 in other patients (median 6, SE 0.3) (Mann-Whitney U-test; P = 0.04). Multiple regression analysis revealed that Chalkley count, not lymph node status, independently predicted CK-19 RGE status (P = 0.04; odds ratio 1.38; 95% confidence interval 1.009-1.882). Blood parameters reflecting angiogenesis and coagulation were positively correlated with Chalkley count and/or CK-19 RGE. Our data are in support of an association between elevated relative microvessel area of the primary tumour and the presence of bone marrow micrometastases in breast cancer patients with operable disease, and corroborate the paracrine and endocrine role of interleukin-6 and the involvement of coagulation in breast cancer growth and metastasis.
Benoy
Ina H
IH
Translational Cancer Research Group Antwerp, Laboratory of Pathology, University of Antwerp/University Hospital Antwerp, Edegem, Belgium. ina.benoy@pandora.be <ina.benoy@pandora.be>
Salgado
Roberto
R
Elst
Hilde
H
Van Dam
Peter
P
Weyler
Joost
J
Van Marck
Eric
E
Scharpé
Simon
S
Vermeulen
Peter B
PB
Dirix
Luc Y
LY
D000368:Aged; D019046:Bone Marrow Neoplasms / Q000556:secondary*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000473:pathology*; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006133:Growth Substances / Q000097:blood; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D007633:Keratins / Q000032:analysis / Q000235:genetics*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D009389:Neovascularization, Pathologic; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D012044:Regression Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity
D016207:Cytokines; D006133:Growth Substances; D015850:Interleukin-6; D012333:RNA, Messenger; D007633:Keratins
Clin Cancer Res. 2000 Jan;6(1):139-46
10656442
Nat Med. 1999 Apr;5(4):434-8
10202935
Nat Med. 2000 Apr;6(4):389-95
10742145
Ann N Y Acad Sci. 2000 May;902:249-62; discussion 262-4
10865845
Nature. 2000 Sep 14;407(6801):249-57
11001068
J Pathol. 2001 Oct;195(3):336-42
11673831
Methods. 2001 Dec;25(4):402-8
11846609
Br J Cancer. 2002 Feb 1;86(3):389-95
11875705
Histopathology. 2001 Dec;39(6):551-3
11903570
Eur J Cancer. 2002 Aug;38(12):1564-79
12142044
Lancet. 2002 Aug 31;360(9334):683-9
12241875
Br J Cancer. 2002 Dec 2;87(12):1437-44
12454774
Int J Cancer. 2003 Feb 20;103(5):642-6
12494472
Br J Surg. 2003 Mar;90(3):290-301
12594663
Br J Cancer. 2003 Mar 10;88(5):718-25
12618881
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9
12714683
Histopathology. 2003 Jun;42(6):530-40
12786888
J Clin Oncol. 2003 Jul 1;21(13):2609-15
12829682
Cell. 2003 Jun 27;113(7):821-3
12837240
Cancer Res. 2003 Sep 15;63(18):5679-84
14522883
Int J Cancer. 2004 Feb 10;108(4):620-7
14696130
Cancer Res. 2004 May 1;64(9):2941-55
15126324
N Engl J Med. 1986 Dec 25;315(26):1650-9
3537791
Cancer. 1989 Jan 1;63(1):181-7
2910416
N Engl J Med. 1991 Jan 3;324(1):1-8
1701519
J Clin Oncol. 1991 Oct;9(10):1749-56
1919627
J Cell Physiol. 1994 May;159(2):245-55
8163565
Am J Pathol. 1998 Feb;152(2):399-411
9466566
Br J Cancer. 1999 May;80(5-6):892-7
10360671
Br J Cancer. 2004 Nov 15;91(10):1813-20
15505629
Lancet. 1995 Nov 18;346(8986):1334-5
7475773
Br J Cancer. 1996 Jan;73(1):79-82
8554988
J Natl Cancer Inst. 1997 Jul 16;89(14):1044-9
9230886
Am J Pathol. 1997 Nov;151(5):1417-23
9358768
Nat Med. 1998 Aug;4(8):923-8
9701244
N Engl J Med. 2000 Feb 24;342(8):525-33
10684910